News

IV/IM meloxicam is a proprietary, Phase III-ready, long-acting COX-2 NSAID designed for the management of moderate to severe acute pain. As part of the deal, Recro paid Alkermes

In February 2015, the US Food and Drug Administration (FDA) granted approval for Liletta based on the largest hormonal IUD trial conducted in the US, A Comprehensive Contraceptive

Under the five-year deal, AstraZeneca will have access to PatientsLikeMe’s global network in support of its patient-driven research initiatives. AstraZeneca Global Medicines Development EVP Briggs Morrison said: "Understanding

In the multicenter, randomized, double-blind, placebo-controlled, multi-dose trial (Heparc-2004), ARC-520 will be administered intravenously to patients with chronic immune active HBV infection maintained on entecavir or tenofovir therapy.

Both the parties will conduct a two-year research program for the development of small molecules targeting the cell surface protein ADAM8, which has been linked to tumor survival,

PAH is a life-threatening disease involving endothelial dysfunction, pulmonary vasoconstriction, vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. In addition, PAH involves skeletal muscle dysfunction that contributes to

The company said that IND remains on partial clinical hold with regard to doses above 0.24 mg/kg/day in healthy volunteers. The randomized, single-blind, placebo-controlled TKM-Ebola Phase I clinical

In February 2015, the company submitted the investigational new drug (IND) application for Actimmune in the treatment of FA. The company has also announced plans to initiate a

Further to this deal, Celgene will purchase Mesoblast stock and hold a six-month right of first refusal to certain disease fields. As part of the agreement, Celgene will